Activity of ceftazidime against gram-negative bacilli from paediatric patients

J. D. Nelson, S. Shelton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Clinically relevant bacterial isolates from paediatric patients were tested for in-vitro susceptibility to ceftazidime. They included 54 strains of coliform bacilli from infants with meningitis, 41 strains of coliforms which were multiply-resistant to aminoglycosides, 65 strains of Pseudomonas aeruginosa from burn unit patients, cystic fibrosis patients and other clinical specimens, and 16 miscellaneous nonfermentative bacilli. The range of MICs for coliform bacilli was from ≤ 0.06 to 0.5 mg/l and the MIC90 was 0.25 mg/l. One psuedomonas isolate and two nonfermenters were resistant, but the others were susceptible with an MIC90 of 8 mg/l and a median MIC of 2 mg/lg. Ceftazidime has comparable activity to moxalactam, ceftriaxone and cefotaxime against coliform bacilli and greater activity against psuedomonas strains.

Original languageEnglish (US)
Pages (from-to)179-181
Number of pages3
JournalJournal of Antimicrobial Chemotherapy
Volume8
Issue numberSuppl.B.
StatePublished - 1981

Fingerprint

Ceftazidime
Enterobacteriaceae
Bacillus
Pediatrics
Moxalactam
Burn Units
Cefotaxime
Ceftriaxone
Aminoglycosides
Meningitis
Cystic Fibrosis
Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Activity of ceftazidime against gram-negative bacilli from paediatric patients. / Nelson, J. D.; Shelton, S.

In: Journal of Antimicrobial Chemotherapy, Vol. 8, No. Suppl.B., 1981, p. 179-181.

Research output: Contribution to journalArticle

@article{05d29a8122f249d5b8f8e807f3f20287,
title = "Activity of ceftazidime against gram-negative bacilli from paediatric patients",
abstract = "Clinically relevant bacterial isolates from paediatric patients were tested for in-vitro susceptibility to ceftazidime. They included 54 strains of coliform bacilli from infants with meningitis, 41 strains of coliforms which were multiply-resistant to aminoglycosides, 65 strains of Pseudomonas aeruginosa from burn unit patients, cystic fibrosis patients and other clinical specimens, and 16 miscellaneous nonfermentative bacilli. The range of MICs for coliform bacilli was from ≤ 0.06 to 0.5 mg/l and the MIC90 was 0.25 mg/l. One psuedomonas isolate and two nonfermenters were resistant, but the others were susceptible with an MIC90 of 8 mg/l and a median MIC of 2 mg/lg. Ceftazidime has comparable activity to moxalactam, ceftriaxone and cefotaxime against coliform bacilli and greater activity against psuedomonas strains.",
author = "Nelson, {J. D.} and S. Shelton",
year = "1981",
language = "English (US)",
volume = "8",
pages = "179--181",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "Suppl.B.",

}

TY - JOUR

T1 - Activity of ceftazidime against gram-negative bacilli from paediatric patients

AU - Nelson, J. D.

AU - Shelton, S.

PY - 1981

Y1 - 1981

N2 - Clinically relevant bacterial isolates from paediatric patients were tested for in-vitro susceptibility to ceftazidime. They included 54 strains of coliform bacilli from infants with meningitis, 41 strains of coliforms which were multiply-resistant to aminoglycosides, 65 strains of Pseudomonas aeruginosa from burn unit patients, cystic fibrosis patients and other clinical specimens, and 16 miscellaneous nonfermentative bacilli. The range of MICs for coliform bacilli was from ≤ 0.06 to 0.5 mg/l and the MIC90 was 0.25 mg/l. One psuedomonas isolate and two nonfermenters were resistant, but the others were susceptible with an MIC90 of 8 mg/l and a median MIC of 2 mg/lg. Ceftazidime has comparable activity to moxalactam, ceftriaxone and cefotaxime against coliform bacilli and greater activity against psuedomonas strains.

AB - Clinically relevant bacterial isolates from paediatric patients were tested for in-vitro susceptibility to ceftazidime. They included 54 strains of coliform bacilli from infants with meningitis, 41 strains of coliforms which were multiply-resistant to aminoglycosides, 65 strains of Pseudomonas aeruginosa from burn unit patients, cystic fibrosis patients and other clinical specimens, and 16 miscellaneous nonfermentative bacilli. The range of MICs for coliform bacilli was from ≤ 0.06 to 0.5 mg/l and the MIC90 was 0.25 mg/l. One psuedomonas isolate and two nonfermenters were resistant, but the others were susceptible with an MIC90 of 8 mg/l and a median MIC of 2 mg/lg. Ceftazidime has comparable activity to moxalactam, ceftriaxone and cefotaxime against coliform bacilli and greater activity against psuedomonas strains.

UR - http://www.scopus.com/inward/record.url?scp=0019789763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019789763&partnerID=8YFLogxK

M3 - Article

C2 - 19802983

AN - SCOPUS:0019789763

VL - 8

SP - 179

EP - 181

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - Suppl.B.

ER -